hotspot -WSS

hotspot

author：entertainment 2025-09-30 00:36:16 - browse：6

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： CommonSpirit Health keeps growing, even as it loses money

explore

focus

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why Charlie Gard's case is so disturbing to Americans

Senate panel eyes new effort on drug shortages

A virus, fished out of a lake, may have saved a man’s life

FDA panel signals lack of confidence in Amgen cancer drug data

Ukraine and a new approach to mental health in war

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Virginia high school admissions case could be legal follow

Medical student insurance fails on mental health care coverage

Affirmative action in medical school literally saved lives

Was Amgen transparent enough on FDA's concern on cancer drug?

Psychedelics group wrestles with new pharma identity

Biotech stock slump in 2023: awaiting the turnaround

In Memoriam: Notable people who died in 2023

A Q&A with the global head of Boehringer Ingelheim's innovation unit

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How AI helped researchers track recovery from depression

entertainment

FDA rejects Alnylam's heart disease treatment over insufficient data

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Stroke deaths set to near 10 million globally by 2050

Why are Kaiser Permanente staff considering a strike?

When women are denied an abortion, their children fare worse than peers

Biotech stock slump in 2023: awaiting the turnaround

explore

focus

focus

knowledge